{"id":39732,"date":"2025-08-20T11:42:25","date_gmt":"2025-08-20T03:42:25","guid":{"rendered":"https:\/\/flcube.com\/?p=39732"},"modified":"2025-08-20T11:42:26","modified_gmt":"2025-08-20T03:42:26","slug":"wuxi-biologics-reports-16-1-revenue-growth-in-h1-2025-launches-wuxihigh-2-0-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39732","title":{"rendered":"WuXi Biologics Reports 16.1% Revenue Growth in H1 2025, Launches WuXiHigh 2.0 Platform"},"content":{"rendered":"\n

WuXi Biologics (Cayman) Inc. (HKG: 2269<\/a>), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced its unaudited interim results for the first half of 2025. The company reported a 16.1% year-on-year (YoY) increase in revenue to RMB 9,953.2 million. Revenue from continuing operations grew by 20.2%. IFRS gross profit rose by 27.0% YoY to RMB 4,252.9 million, with an IFRS gross profit margin of 42.7%.<\/p>\n\n\n\n

Growth Drivers<\/strong>
The revenue growth was primarily attributed to:<\/p>\n\n\n\n

    \n
  1. The success of the Group’s “Follow and Win the Molecule” strategies, supported by leading technology platforms and strong execution.<\/li>\n\n\n\n
  2. An expanded service range across the biologics value chain, including discovery, pre-IND development, and clinical and commercial manufacturing, with significant growth in platforms such as antibody-drug conjugates (ADCs) and bi- & multi-specific antibodies.<\/li>\n\n\n\n
  3. Increased research services revenue driven by cutting-edge technologies.<\/li>\n\n\n\n
  4. Enhanced utilization of existing and newly expanded capacity, including the ramp-up of the European manufacturing facility.<\/li>\n<\/ol>\n\n\n\n

    Project and Backlog Highlights<\/strong>
    In the first half of 2025, the Group added 86 integrated projects, bringing the total to 864, with over half originating from U.S. clients. The Group supports 67 late-stage and 24 commercial projects. The total backlog increased to USD 20.34 billion, with the backlog within 3 years reaching USD 4.21 billion.<\/p>\n\n\n\n

    WuXiHigh 2.0 Platform<\/strong>
    During the reporting period, WuXi Biologics launched WuXiHigh 2.0, its next-generation high-throughput formulation platform for high-concentration biologics. This platform enables protein concentrations of up to 230 mg\/mL and reduces viscosity by up to 90%, while maintaining stability and injectability.    -Fineline Info & Tech<\/a><\/p>\n\n\n\n